FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
BVF PARTNERS L P/IL
  2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [KYMR] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) __X__ Other (specify below)
See Remarks and Footnotes
(Last)
(First)
(Middle)
44 MONTGOMERY STREET, 40TH FLOOR		 3. Date of Earliest Transaction (Month/Day/Year)
08/20/2024
(Street)

SAN FRANCISCO, CA 94104		 4. If Amendment, Date Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) 		7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.0001 par value (1)               2,656,191 D (2)  
Common Stock, $0.0001 par value (1)               2,104,075 D (3)  
Common Stock, $0.0001 par value (1)               294,632 D (4)  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5) 		6. Date Exercisable and Expiration Date
(Month/Day/Year) 		7. Title and Amount of Underlying Securities
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4) 		10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4) 		11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Pre-Funded Warrants to Purchase Common Stock (1) $ 0.0001 08/20/2024   P   201,546     (6)   (6) Common Stock, $0.0001 par value 201,546 $ 40.7499 201,546 D (2)  
Pre-Funded Warrants to Purchase Common Stock (1) $ 0.0001 08/20/2024   P   156,742     (6)   (6) Common Stock, $0.0001 par value 156,742 $ 40.7499 156,742 D (3)  
Pre-Funded Warrants to Purchase Common Stock (1) $ 0.0001               (6)   (6) Common Stock, $0.0001 par value 550,425   550,425 D (2)  
Pre-Funded Warrants to Purchase Common Stock (1) $ 0.0001               (6)   (6) Common Stock, $0.0001 par value 375,856   375,856 D (3)  
Pre-Funded Warrants to Purchase Common Stock (1) $ 0.0001               (6)   (6) Common Stock, $0.0001 par value 52,733   52,733 D (4)  
Stock Option (Right to Buy) (5) $ 31.2               (7) 06/17/2034 Common Stock, $0.0001 par value 16,000   16,000 I (5) See footnote (5)
Stock Option (Right to Buy) (5) $ 20               (8) 08/19/2030 Common Stock, $0.0001 par value 40,127   40,127 I (5) See footnote (5)
Stock Option (Right to Buy) (5) $ 49.1               (8) 06/15/2031 Common Stock, $0.0001 par value 20,063   20,063 I (5) See footnote (5)
Stock Option (Right to Buy) (5) $ 14.18               (8) 06/14/2032 Common Stock, $0.0001 par value 12,000   12,000 I (5) See footnote (5)
Stock Option (Right to Buy) (5) $ 27.67               (8) 06/14/2033 Common Stock, $0.0001 par value 12,000   12,000 I (5) See footnote (5)

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
BVF PARTNERS L P/IL
44 MONTGOMERY STREET
40TH FLOOR
SAN FRANCISCO, CA 94104		   X     See Remarks and Footnotes
BIOTECHNOLOGY VALUE FUND L P
44 MONTGOMERY STREET
40TH FLOOR
SAN FRANCISCO, CA 94104		   X     See Remarks and Footnotes
BVF I GP LLC
44 MONTGOMERY STREET
40TH FLOOR
SAN FRANCISCO, CA 94104		   X     See Remarks and Footnotes
BIOTECHNOLOGY VALUE FUND II LP
44 MONTGOMERY STREET
40TH FLOOR
SAN FRANCISCO, CA 94104		   X     See Remarks and Footnotes
BVF II GP LLC
44 MONTGOMERY STREET
40TH FLOOR
SAN FRANCISCO, CA 94104		   X     See Remarks and Footnotes
Biotechnology Value Trading Fund OS LP
P.O. BOX 309 UGLAND HOUSE
GRAND CAYMAN, E9 KY1-1104		   X     See Remarks and Footnotes
BVF Partners OS Ltd.
P.O. BOX 309 UGLAND HOUSE
GRAND CAYMAN, E9 KY1-1104		   X     See Remarks and Footnotes
BVF GP HOLDINGS LLC
44 MONTGOMERY STREET
40TH FLOOR
SAN FRANCISCO, CA 94104		   X     See Remarks and Footnotes
BVF INC/IL
44 MONTGOMERY STREET
40TH FLOOR
SAN FRANCISCO, CA 94104		   X     See Remarks and Footnotes
LAMPERT MARK N
44 MONTGOMERY STREET
40TH FLOOR
SAN FRANCISCO, CA 94104		   X     See Remarks and Footnotes

Signatures

 BVF Partners L.P., By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President   08/22/2024
**Signature of Reporting Person Date

 Biotechnology Value Fund, L.P., By: BVF I GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer   08/22/2024
**Signature of Reporting Person Date

 BVF I GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer   08/22/2024
**Signature of Reporting Person Date

 Biotechnology Value Fund II, L.P., By: BVF II GP LLC, its general partner, By: /s/ Mark N. Lampert, Chief Executive Officer   08/22/2024
**Signature of Reporting Person Date

 BVF II GP LLC, By: /s/ Mark N. Lampert, Chief Executive Officer   08/22/2024
**Signature of Reporting Person Date

 BVF Partners OS Ltd., By: BVF Partners L.P., its sole member, By: BVF Inc., its general partner, By: /s/ Mark N. Lampert, President   08/22/2024
**Signature of Reporting Person Date

 Biotechnology Value Trading Fund OS LP, By: BVF Partners L.P., its investment manager, BVF Inc., its general partner, By: /s/ Mark N. Lampert, President   08/22/2024
**Signature of Reporting Person Date

 BVF GP Holdings LLC, By: /s/ Mark N. Lampert, Chief Executive Officer   08/22/2024
**Signature of Reporting Person Date

 BVF Inc., By: /s/ Mark N. Lampert, President   08/22/2024
**Signature of Reporting Person Date

 /s/ Mark N. Lampert   08/22/2024
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
(2) Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
(3) Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
(4) Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
(5) Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
(6) The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to certain conditions and limitations, and do not expire.
(7) The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 18, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders.
(8) The shares subject to the option have fully vested.
 
Remarks:
For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of the Reporting Persons may be deemed to be a director by deputization of the Issuer due to a member of Partners, Gorjan Hrustanovic, serving on the Board of Directors of the Issuer, and his agreement to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.